Invega Trinza, Pentasa, and Abilify LAI Top Viatris’ First Complex Ambitions

Recent First-Time Restasis Launch Among $600m Of 2022 Product Launches

 
• By Dean Rudge
  
Sprinting
Viatris is hoping to lead the race in several key launches • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business